ClinicalTrials.gg
RecruitingNCT07373444Updated Nov 6, 2026

Westlake Aging Cohort (WeAC)

An observational study in Aging, Cognition Improvement and Cognition Disorders, sponsored by Westlake University. Recruiting at 2 sites in China. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Westlake University · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,800
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Cognition Disorders with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Cognition Disorders · China.

Started
2026
with 4 others
Observational
8 of 23
2 open now
Primary completion
2030-12
later than 10 of 10 live
Registered
20th of 23
by date

Among the 23 studies in Cognition Disorders with a site in China, this one is one of 5 that started in 2026, is one of 8 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 20th registered.

Cognition Disorders

399 studies on the registry are indexed under Cognition Disorders; 72 are open to participants now.

Browse Cognition Disorders studies →

Open to participants now

11 of the 23 studies in Cognition Disorders with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Cognition Disorders studies recruiting now, 20 (43%) set no upper age limit and 11 (24%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cognition Disorders with a site in China, or all of them as a file.
02

Study summary

The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.

Read the detailed description

The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.

03

Conditions studied

  • Aging
  • Cognition Improvement
  • Cognition Disorders
  • Cognition

Browse trials for

Keywords

  • aging
  • cognition
  • gut microbiota
  • multi-omics
  • brain
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All participants must be Chinese residents, regardless of their ethnicity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 55 and 90 years (inclusive) at baseline.
  2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
  3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
  4. scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
  5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
  6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.

Exclusion criteria

Exclusion Criteria:

  1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
  2. Current use of psychoactive medications or any other drugs that may affect the study.
  3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
  4. Participants with any other diseases that may affect the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,800 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Cognitive function

    Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians.

    Time frame: 48 months

  2. Gut microbiome

    The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.

    Time frame: 48 months

Secondary outcomes

  1. Brain magnetic resonance imaging

    Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants.

    Time frame: 48 months

  2. Positron emission tomography

    Assess the brain function and neurological disorders by positron emission tomography (PET).

    Time frame: 48 months

  3. Brain images relevant inspections

    Other brain image relevant inspections required for study to measure brain structure and function of participants.

    Time frame: 48 months

  4. Electroencephalogram

    Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking.

    Time frame: 48 months

  5. Blood biochemical parameters

    Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer.

    Time frame: 48 months

  6. Serum inflammatory factors

    Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants.

    Time frame: 48 months

  7. Health and behavior monitoring

    Use fitness trackers to record the physiological and behavioral data of participants.

    Time frame: 48 months

  8. Sleep data measurement

    Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality.

    Time frame: 48 months

  9. Continuous glucose monitoring

    Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants.

    Time frame: 48 months

  10. Environmental measurement

    Use the environmental monitoring device to measure various exposure factors in the participants' living environment.

    Time frame: 48 months

  11. Multi-omics data

    Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc.

    Time frame: 48 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2030, 54 months after the start.

Of 43 non-industry observational studies under Cognition Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 89. This study's planned 54 months is above that.

Counting every sponsor, half of 44 studies reached it within 41 months; a quarter within 13 and three quarters within 89.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jun 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Jan 28, 2026
StartActual
Jun 3, 2026was Jan 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2031
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Hangzhou First People's Hospital · Hangzhou, Chinano status→Recruiting
  • Hangzhou Third People's Hospital · Hangzhou, Chinano status→Recruiting
Nov 6, 2026
Start date
Jan 1, 2026→Jun 3, 2026 (actual)
Nov 6, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Hangzhou First People's Hospital · Hangzhou, ChinaContact added z•••@westlake.edu.cn · •••5303
  • Hangzhou Third People's Hospital · Hangzhou, ChinaContact added (no phone or email listed)Contact added (no phone or email listed)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Hangzhou First People's Hospital · Hangzhou, Chinano status→Recruiting
    • Hangzhou Third People's Hospital · Hangzhou, Chinano status→Recruiting
    Start date Jan 1, 2026→Jun 3, 2026 (now actual)
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Hangzhou First People's Hospital · Hangzhou, ChinaContact added z•••@westlake.edu.cn · •••5303
    • Hangzhou Third People's Hospital · Hangzhou, ChinaContact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07373444
Lead sponsor
Westlake University
Collaborators
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, The Third People's Hospital of Hangzhou
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Jun 3, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 6, 2026

Study contacts

Ju-Sheng Zheng, PhD
Contact
zhengjusheng@westlake.edu.cn
86-0571-86915303
Ju-Sheng Zheng, PhD
principal investigator · Westlake University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion